Analyst Profile

Followed by 277 followers
.
Christopher Marai

Christopher Marai

Nomura
Wall Street Analyst
#1,917 out of 8,166 Wall Street Analysts
#4,084 out of 24,458 experts

Success Rate

45%
180 out of 404 transactions made a profit

Average Return

+4.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Christopher Marai's trades since 2014 and holding each position for 1 Year would result in 44.55% of your transactions generating a profit, with an average return of 4.1% per rating.

Stock Rating Distribution

683Ratings
81.99% Buy
12.30% Hold
5.71% Sell
Distribution of Christopher Marai's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Prothena Corporation
(PRTA)
Rating:Buy
Date:Jul 09, 2020 - Jul 09, 2021
Return:+390.30%
The most profitable rating made by Christopher Marai

Christopher Marai's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
MDVN
Medivation
Apr 30, 2014
Buy
Reiterated
1Ratings
100%
+100.50%
Regulus
May 14, 2014
Hold
Assigned
2Ratings
0.00%
DYAX
Dyax Corp
May 14, 2014
Hold
Assigned
2Ratings
0%
-28.10%
Insmed
May 14, 2014
Hold
Assigned
3Ratings
100%
+20.10%
Addex Therapeutics
May 14, 2014
Hold
Assigned
1Ratings
0.00%
XNPT
XenoPort
May 14, 2014
Hold
Assigned
1Ratings
0.00%
Fortress Biotech
May 14, 2014
Hold
Assigned
3Ratings
0.00%
Novavax
May 14, 2014
Hold
Assigned
1Ratings
0.00%
PCYC
Pharmacyclics
May 14, 2014
Hold
Assigned
3Ratings
0%
-15.40%
CASC
Cascadian Therapeutics
May 14, 2014
Hold
Assigned
1Ratings
0.00%
List of latest recommendations made by Christopher Marai. Click to expand and see Christopher Marai's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >